CannTrust Holdings Inc. (NYSE: CTST) shares dropped on Thursday after the firm announced the pricing of its secondary offering. The company intends to price its 36.36 million shares at $5.50 per share, with an overallotment option for an additional 5.45 million shares. At this price, the entire offering is valued up to roughly $230 million.
Out of the 36.36 million shares being sold, 30.90 million are being sold by the company, while 5.45 million are being sold by selling shareholders.
The underwriters for the offering are Merrill Lynch, Citigroup, Credit Suisse, RBC Capital Markets, Jefferies and Canaccord Genuity.
For some quick background: CannTrust is a federally regulated licensed producer of medical and recreational cannabis in Canada. Founded by pharmacists, CannTrust brings more than 40 years of pharmaceutical and health care experience to the medical cannabis industry and serves more than 69,000 medical patients with its dried, extract and capsule products.
CannTrust intends to use the net proceeds of the offering for general corporate purposes, including cultivation and facility expansion, expanded outdoor growing, international expansion, enhanced extraction capacity, upgrades for GMP Certification and biosynthesis development.
Excluding Thursday’s move, CannTrust had outperformed the broad markets, with the stock up about 33.5% year to date.
Shares of CannTrust were last seen down about 12% at $5.66, in a post-IPO range of $4.76 to $10.17.
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
